ISARIC
  • Home
  • About us
    • Membership
    • Fellowships
    • People
    • News
    • Events
  • Research
    • Monkeypox
    • COVID Resources
    • Bubonic plague
    • Lassa fever resources
    • Severe Acute Hepatitis
    • Ebola
  • Document Library
Select Page
ISARIC member compares COVID-19 hospital admissions during first and second waves in Brazil

ISARIC member compares COVID-19 hospital admissions during first and second waves in Brazil

by Liliana Resende | Aug 25, 2021 | News

With more than 16 million confirmed cases, it is safe to say that Brazil is one of the most affected countries by the COVID-19 pandemic. With this in mind, Fernando Bozza (Oswaldo Cruz Foundation (Fiocruz), Brazil) ISARIC’s member network Principal Investigator,...

Researchers start new investigation into Long COVID core outcome set

by Liliana Resende | Aug 11, 2021 | News

A group of researchers started this project with the aims of understanding what are the core outcomes for patients living with Long COVID. The World Health Organization (WHO) recently called countries to prioritise recognition, rehabilitation and research for the...
ISARIC COVID-19 clinical database passes the half million patient records mark

ISARIC COVID-19 clinical database passes the half million patient records mark

by Liliana Resende | Jul 16, 2021 | News

On its 10th anniversary, University of Oxford’s ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium) demonstrates the crucial role of global preparedness and collaboration for advancing knowledge on infectious disease pandemics. COVID-19...

Children older than 6 and with reported allergic diseases are at greater risk of Long COVID, paediatric study finds

by Liliana Resende | Jul 14, 2021 | News

Researchers from ISARIC (International Severe Acute Respiratory and emerging Infection Consortium) paediatric Long Covid working group in the UK, Sechenov University and Z.A. Bashlyaeva Children’s Municipal Clinical Hospital in Russia ran the largest study to date on...

Time to reconsider the role of ribavirin in Lassa fever

by Liliana Resende | Jul 8, 2021 | News

Ribavirin is the only available Lassa fever–specific treatment and has been used routinely for over 25 years. However, Ribavirin is not licensed for Lassa fever, its mechanism of action is unclear, it’s expensive and hard to source, and it has well-known...
« Older Entries





© ISARIC 2020 | Privacy Policy | Accessibility | Website Terms of Use | Contact Us | Site by Herd

Cookies Policy

Our Website uses cookies to improve your experience. Please visit our Cookies page for more information about cookies and how we use them.

Close